Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients
Saved in:
| Main Authors: | Edmund Chiong, Ziteng Wang, Eleanor Jing Yi Cheong, Yi Chen Yao, Sin Mun Tham, Revathi Periaswami, Poh Choo Toh, Ziting Wang, Qing Hui Wu, Woon Chau Tsang, Arshvin Kesavan, Alvin Seng Cheong Wong, Patrick Thomas Wong, Felicia Lim, Shuaibing Liu, Eric Chun Yong Chan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Communications |
| Online Access: | https://doi.org/10.1002/cac2.70035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prescription pattern of abiraterone in Brazil - a survey of medical oncologists
by: João Pedro Homse-Netto, et al.
Published: (2023-08-01) -
Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer
by: Eva Streckova, et al.
Published: (2025-01-01) -
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01) -
Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01) -
A pilot clinical study of developing an External Assist Targeting Device for rapid and precise renal calyx access during percutaneous nephrolithotomy
by: Qinghui Wu, et al.
Published: (2023-07-01)